Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Q1 Combined Financial Statements - Rafarma Pharmaceuticals Inc @RafarmaPharma $RAFA #Rafarma Pharmaceuticals Inc.
Filing Link...
https://otcmarkets.com/otcapi/company/financial-report/333781/content
Q1 HIGHLIGHTS
> $14.3 Million Revenue
> $4.3 Million Gross Profit
> $81 Million Total Assets
> $9.9 Million Cash
*Note Currency Anomaly Adjustment in Q1
https://acrobat.adobe.com/link/review?uri=urn:aaid:scds:US:eac00c56-1835-3f6d-89f9-a29c85e037ba
But its not looking good
I hope RAFA can get back to $0.70 one day !!!!!!!!!!!!!!!!!!
IB_
I am. I’ve stuck with it for 2-3 years. It has not been fun, but Ilya has created and shared a long-term strategic plan and, while communications have been fractured and progress slower than I have hoped, rafa continues to deliver on everything promised. I’ve picked up 20-30k in past 2-3 months. We shall see.
$RAFA Rafarma Pharmaceuticals Inc *2021 FINANCIAL REPORT*
Link .. https://otcmarkets.com/otcapi/company/financial-report/325660/content
> 2021 SALES $77.4 Million
> NET INCOME $11.6 Million
> EARNINGS PER SHARE $0.132c
> CASH $13.6 Million
> TOTAL ASSETS $89.3 Million
> Shares O/S 87.8m
ATTORNEY LETTER WITH RESPECT TO CURRENT INFORMATION –
RAFARMA PHARMACEUTICALS, INC. (RAFA) - http://www.otcmarkets.com/financialReportViewer?symbol=RAFA&id=326438 THE LAW OFFICES OF M. AMBER BARGER, PLLC
Have ppl lost interest in this stock.. no msgs in a cple of weeks .. even after it announced 2021 results and stock has doubled from its low?
any one still interested in this stock .. the message board is dead on RAFA
New website with video message from CEO under news page: www.noyarp.com
It doesn't because RAFA is just another loser stock like the others !!!!!!!!!!!!!!!!!!!!!!!!!!
IB_
Does it truly matter what or when the audit was supposed to be? They can literally say anything they want in it.
Glad I got out of one penny stock ahead of big losses
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=167142091
When was that "audit" suppose to have happened, 2019 ?????????????????????
Who was the main Promotor of RAFA a year or so ago ?????????????????????
IB_
It's the Putin put!!!
Well, it's all how you look at it. I'm sure the audit will help.
RAFA is looking BAD .................................
I'm so glad I wasn't conned into buying it,
IB_
I agree !!!! There will always be an excuse ........................ until the END,
IB_
It is a negative growth company and, no, COVID is not an excuse for it. I wonder if the Russian will withdraw his companies from RAFA - as easily as he put them in. Just maybe, there is rally nothing to audit at this point.
Yeah when is that audit that has been coming for soooo long !!!!!!!!!!!!
Look at RAFA fall lower & lower,
LoL LoL,
IB_
Just waiting for the audit to right this ship. Don't worry people, all will be fine and we'll be living on that island soon enough.
RAFA will be sub penny soon !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
IB_
It's the stock of someone's life; just like sub-penny PRED.
Why is RAFA always falling ................................
IB_
I could see bankruptcy in RAFA's future !!!!!!!!!!!!!!!!!!!!!!!!!!!!
IB_
Why are Russian controlled stocks down today. Any news?
Or lower. with the oligarchs being punished, could go bankrupt.
RAFA could be pushed into the teens with this war going on !!!!!!!!!!!!!!
IB_
Why buy more RAFA when it is going to sub penny per share ???????????????
IB_
What do you mean?… I’ve picked up a few 1,000
RAFA hasn't traded since the 18th?
RAFA is really looking bad !!!!!!!!!!!!!!!!!!!!!!!!!!!!!
I believe bankruptcy is not far into the future,
IB_
I believe RAFA will file for bankruptcy soon !!!!!!!!!!!!!!!!!!!!!
IB_
Another Bird Man island stock that looks more like Atlantis!
RAFA's future looks bleak !!!!!!!!!!!!!!!!!!!!!!!!!!!
IB_ :(
Is RAFA just another scam stock !!!!!!!!!!!!!!!!!!!!!!!
LoL LoL,
IB_
And it's the other stock of someone's life!!! ??
Their 'audit' can say anything it wants. It's OTC and the only people who review the audit work/own RAFA. Stock in Pred 2.0.
It could be lies, lies, lies. After all we are dealing with a Russian here that would never be prosecuted
Ridiculous to even say that. there is nothing similar between those two companies. Cash cash cash
This is like PRED. The company doesn't care about its shareholders. They are still doing the audit that lasts forever. One has to wonder the validity of the numbers published and reported to OTC markets.
Agreed. There is a Twitter account (likely owned/run by ???) and a YouTube channel where Ilya posts videos from time to time.
I have called that # several times and talked to the PR rep. For 3 yrs he has shared the same messages that have been published.
I've emailed with no response. This company doesn't care about it's investors as we watch our investment deep dive. No words from the CEO on uplisting, or when the new audit we must wait for is expected to be completed.
Has anyone tried to call the company? No one answers. How is that possible.
Pulled from their last PR.
For more information contact:
RAFARMA (307) 429-2029
RAFA mgt was in New York two weeks ago giving a presentation. Where any of you here at the presentation?
Why would you call a company that did $51 million in revenue and made $18 million in gross profit in the first 3 quarters of 2021 a bust? It seems to be the opposite.
RAFA getting a nice spike today !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
Be Careful,
IB_ ;)
$RAFA RAFA Enters into Negotiations with JINR for Ultra-Cutting Edge Nuclear Research
Press Release | 12/21/2021
Nicosia, Cyprus, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) is currently negotiating with the Joint Institute for Nuclear Research (JINR), an international intergovernmental scientific organization established by eleven founding countries in 1956 and registered by the United Nations. The purpose of the current negotiations is the development and implementation of Rafarma Pharmaceuticals’ projects related to nuclear medicine technologies, radiopharmaceuticals, radiotherapy and promising projects in related industries. Currently, our company produces devices for nuclear medicine, such as microspheres with Yttrium-90, micro sources based on Iodine-125, therapeutic and surgical gels containing isotopes.
Rafarma Pharmaceuticals is actively developing a muon radiography project based on emulsion detectors using artificial intelligence. This is a promising method of studying the internal structure of large natural and industrial facilities which allows, in particular, to monitor the condition of volcanoes, karst caves, mines, nuclear power complex installations, and provide early detection and forecasting of the development of probable emergencies, as well as conducting geological exploration in space.
Rafarma is excited about the cooperation with JINR, whose scientific and experimental facilities are geographically located in the Dubna, the science city of the Moscow region, in the Russian Federation. It is a world-renowned scientific center, which is a unique example of successful integration of theoretical and experimental research with the development and application of the latest technologies along with university academics. JINR's reputation in the world scientific community is very high. The Institute has the only superconducting accelerator of nuclei and heavy ions in both Europe and Asia, with record parameters for conducting experiments on the synthesis of heavy and exotic nuclei, a unique neutron pulse reactor IBR-2 and a proton accelerator and a plastron for proton therapy.
Forward-Looking Statements: This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate,” or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risk, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with OTC Markets. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
For more information contact:
RAFARMA
(307) 429-2029
Followers
|
97
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
6004
|
Created
|
05/17/10
|
Type
|
Free
|
Moderators |
Many OTC stocks are easily overlooked because they don't get the coverage of peers traded on national exchanges and consequently very few investors have the opportunity to know about them. A perfect example is the recent closing of a reverse merger increasing sales by over 700% and adding sizable international operations of private Biocogency into Rafarma Pharmaceuticals (OTC: RAFA) where the RAFA share price has not yet reflected the new added value.
On October 19, 2020, the merger of Biocogency into Rafarma was announced and went unnoticed. Although important metrics to determine share valuations have soared as a result of the merger, the share price has not yet caught up reflecting the new increased valuations simply because nobody knows about it yet. As word is likely to spread soon, the share price is expected to begin climbing to more fair and reasonable market valuations that could exceed expectations.
About Rafarma Pharmaceuticals
Rafarma Pharmaceuticals, Inc., a multi-product pharmaceutical company, produces and sells cannabis health-related products and specialty pharmaceuticals. The company formerly known as Johnston Acquisition Corp. changed its name to Rafarma Pharmaceuticals, Inc. and is based in Sandy, Utah with a manufacturing and distribution facility in Russia.
Biocogency owns PJSC "Krasfarma", the largest Russian chemical and pharmaceutical production company with more than 50 years of experience in the production of drugs that meet all national and international quality standards.
The Company helps meet the growing needs of health care for high-quality, effective and safe generic pharmaceuticals as well as development and production of innovative pharmaceutical products. Production systems with a strong emphasis on safety are carried out through a coordinated interaction of their quality control department, commercial department, logistics service, and scientific information department and pharmacovigilance services.
A rich history is not the most important thing in the modern pharmaceutical industry. To keep the quality of products on a permanently high level, a program of production modernization is being realized: investments in the company include new industrial lines, engineering systems and control systems, as well as new pharmaceutical products.
Safe and effective generic medicines of PJSC "Kraspharma", which are not inferior in clinical efficacy to the original, but sold at affordable prices, have won the trust of both doctors and patients.
Today PJSC "Kraspharma" is the Eastern Europe and Russia undisputed leader in the production of:
Most of the drugs produced are included in Vital and Essential Drugs List (VED) approved by the Government of the Russian Federation.
The products of PJSC "Kraspharma" are sold in Russia, Eastern Europe, Central Asia and in the countries of the Asia-Pacific region.
What Biocogency Adds to Rafarma
This transformative merger starts by restating Rafarma 2019 sales from $11.4 million to $84 million and delivers impressive growth rates of close to 50%.
The Biocogency group includes Russia-based drug companies Bebig and PJSC Kraspharma and industrial firm Slavich. Bebig is focused on developing therapies and diagnostics for cancer care in the Russian markets, including supplying microsources for the treatment of prostate cancer using low-dose brachytherapy. Kraspharma, Russia's largest chemical and pharmaceutical production company (and crown jewel of the merger), and Slavich, a manufacturer of a variety of products including packaging goods, materials for microelectronics and photo materials, are both steeped in corporate history going back half a century or more in Russia.
Biocogency also brings leadership committed to growing value as measured by the fact the deal was structured to be non-dilutive to existing RAFA shareholders. To that point, Ilia Shpurov has assumed the position of Chairman of the Board, bringing decades of entrepreneurial – and biotech – success to RAFA.
What's in it for RAFA? An Immediate Spike in Revenue and Profits
The merger with Biocogency is a game changer for RAFA operations and the top and bottom lines. Consider that in 2019, RAFA generated revenue of approximately $11.4 million and gross profit of $3.4 million. In the latest quarter, ended July 31, 2020, Rafarma reported revenue of $5.3 million and gross profit of $3.1 million, according to filings with OTC Markets Group.
Those results are going to get an immediate shot of adrenaline.
During fiscal 2019, the Biocogency group reported unaudited consolidated earnings of $73 million and gross profits of $17 million. As a course of becoming fully reporting and planning to uplist, the financial results are being audited and adjusted to meet GAAP standards.
Using the results from 2019, it is easy to extrapolate pro forma revenue of $84.4 million and gross profit of $20.3 million for the combined company. It is those type of financials that will underpin a move to the Nasdaq or NYSE.
More on how the price to sales ratio stacks up to industry comps are discussed here. Several Pharmaceutical market comps point to Rafarma share prices that are many multiples higher than the current price of $1.69.
When it comes to value, it certainly bears mentioning the investments that Biocogency has put into its pipeline and platforms since 2012, which management pegs at more than $120.0 million. Much of this investment has been directed by Shpurov since he bought the Kraspharma during the outbreak of the global financial collapse in 2008 for the purpose of restoring and expanding production volumes post-recession while establishing a high-tech GMP pharmaceutical manufacturer in Krasnoyarsk.
That was accomplished. Today, Kraspharma is a leading producer of wide swath of generic drugs and pharma products spanning antibiotics, blood substitutes, infusion solutions, tuberculosis and preparations for other pharmacological groups. Sales channels extend throughout Russia, Eastern Europe and the Asia-Pacific region.
Widening the Footprint
The plan is for vertical growth by expanding the existing channels while leveraging RAFA relationships for horizontal growth through entering the lucrative North American markets.
In fairness, Russia alone can be a company maker. A huge net importer of medicine, the Russian government is pushing for national security in the supply chain as outlined in the Pharma 2030 Strategy. With that in mind, Statista forecasts the Russian pharmaceutical industry will grow 147% between 2017 and 2030.
During Q1, the Russian pharma market surged 125% year-over-year to about 320 billion Russian rubles (US$4.2 billion). Generic drugs typically dominate the prescription market, accounting for 64.5% of the category in 2017, meaning Kraspharma is in a strong position.
Given the sheer volume of people, Asia is another tremendous market. The Rx market in China alone is forecast to reach $160 billion by 2022, highlighting the market opportunity. With respect to the Asian drug development market, ResearchAndMarkets estimates 6.54% compound annual growth to reach $62.46 billion by 2026.
Still, the U.S. is the Holy Grail as the biggest pharmaceutical market in the world, weighing in at a whopping $484.4 billion in 2018.
Conclusion
With the reverse merger now closed, the newly created Rafarma Pharmaceuticals that now boasts fast-growing operations well in excess of $100 million for 2019 is decidedly undervalued when compared to industry valuations for similar companies. Management plans for uplisting and higher investor awareness programs are soon in the future which will help bring the Rafarma opportunity to the forefront resulting in substantially higher prices and trading volume.
The current price has not yet appreciated to reflect the newly increased sales and valuations and therefore presents an opportunity to astute investors who act now before the story becomes more commonly known.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |